Briggs Morrison - Aug 9, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Aug 9, 2023
Transactions value $
-$501,864
Form type
4
Date filed
8/10/2023, 06:50 AM
Previous filing
Jul 11, 2023
Next filing
Feb 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $464K +52.9K +296.34% $8.77 70.7K Aug 9, 2023 Direct
transaction SNDX Common Stock Sale -$965K -52.9K -74.77% $18.27 17.8K Aug 9, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -52.9K -100% $0.00* 0 Aug 9, 2023 Common Stock 52.9K $8.77 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Following the sales reported in this Form 4, the Reporting Person has a total of 559,142 options to purchase shares of common stock that are vested and immediately exercisable and a total of 247,875 options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $18.02 to $18.41.
F3 This option is fully vested.